"Compared to the reality of the drug industry, my book reads like a vacation post card"
- John le Carré, Author of The Constant Gardner
 
Top News arrow Safety Issues arrow Obama picks Duo to Run FDA: Dr Hamburg, Commissioner; Dr. Sharfstein Deputy
Obama picks Duo to Run FDA: Dr Hamburg, Commissioner; Dr. Sharfstein Deputy Print E-mail
Wednesday, 11 March 2009
Dr. Margaret "Peggy" Hamburg, a former health commissioner in New York City, is the leading candidate to become FDA commissioner, the agency's top job, while Baltimore health chief Joshua Sharfstein is in line to become a deputy commissioner



This just in from the Wall Street Journal online:

"During Margaret "Peggy" Hamburg'sr stint in New York, she won support for a clean-needle-exchange program for drug addicts in order to limit the spread of AIDS. She opposed a "morality oath" demanded by the Board of Education in 1992 while the city was debating abstinence-focused sex education in schools. She said that science-driven public-health practices, and not "moral judgment" or "wishful thinking," should be the basis for educating youngsters on how to avoid AIDS."

"Dr. Sharfstein, 39, was a candidate for the top job but roused strong opposition from some in the drug industry, according to lobbyists who pushed Republicans to oppose him. FDA deputies don't need Senate approval."

~~~~~~~~

THE WALL STREET JOURNAL
MARCH 11, 2009, 9:31 A.M. ET
Former New York Health Chief Is Top Candidate to Run FDA

By ALICIA MUNDY

WASHINGTON -- The Obama administration has settled on two public-health experts to fill top posts at the Food and Drug Administration, people familiar with the matter said.

Margaret "Peggy" Hamburg, a former health commissioner in New York City, is the leading candidate to become FDA commissioner, the agency's top job, while Baltimore health chief Joshua Sharfstein is in line to become a deputy commissioner, the people said.

The search for an FDA chief has dragged on for months, leaving it as one of the few major federal agencies without a nominee. Behind the scenes, pharmaceutical companies and industry-supported patient groups have rallied support for candidates seen as more favorable to industry concerns, while consumer advocates have lobbied for their own choices.

The White House wants to position the FDA commissioner as someone who will lead the agency back to its core mission of public health, and the focus on Dr. Hamburg and Dr. Sharfstein fits that message, said people close to the situation. That strategy could avoid a congressional debate over whether the choices are perceived as pro- or anti-industry.

Dr. Hamburg, 54 years old, was one of the youngest New York City health commissioners and held the job at the time of the first World Trade Center bombing in 1993. She was an assistant secretary of health and human services during the Clinton administration and now works at the Nuclear Threat Initiative, a think tank run by centrist former Democratic Sen. Sam Nunn. She also serves on the board of Henry Schein Inc., a medical-equipment wholesaler.

During her stint in New York, she won support for a clean-needle-exchange program for drug addicts in order to limit the spread of AIDS. She opposed a "morality oath" demanded by the Board of Education in 1992 while the city was debating abstinence-focused sex education in schools. She said that science-driven public-health practices, and not "moral judgment" or "wishful thinking," should be the basis for educating youngsters on how to avoid AIDS.

Dr. Sharfstein, 39, was a candidate for the top job but roused strong opposition from some in the drug industry, according to lobbyists who pushed Republicans to oppose him. FDA deputies don't need Senate approval.

Write to Alicia Mundy at This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Printed in The Wall Street Journal, page A4
 

 
< Prev   Next >
(C) 2012 Alliance for Human Research Protection
CMS installation and website development by Anne Krauss

General Terms & Disclaimer:

This site is not a monologue of truth. It is a catalyst for public debate about medical research conduct. The reader is urged to confront officials to clarify issues mentioned herein. This site is designed strictly to provide information for critical, literary, academic an public usage. A qualified and trustworthy medical professional must be consulted regarding medical issues, treatments, diagnoses, etc.

Please read the General Terms and Conditions of this agreement entirely and carefully before accessing this web site. By accessing the site, you agree to be bound by the terms and conditions listed herein. [continue]